anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will perfume the safety (Phase I) study of 10 patients with silicosis treated with intrabronchial instillation of autologous bone marrow derived mononuclear cells (BMDMC, 2x107) through bronchoscopy. The inclusion criteria is: age between 18-50, chronic and accelerated silicosis, characterized with a fibrotic increase in the last two years, FEV1 \<60% and \> 40%, FVC \> 60% and SaO2 \>90%, while the exclusion criteria were: smoking, active tuberculosis or other infections, cancer, auto-immune disorders, hematological, hepatic or cardiac diseases, and pregnancy. All patients will be subjected to clinical examination, answered questionnaires of quality of life (SGRQ and SF36) and dyspnea score (Borg), performed high resolution CT of thorax, pulmonary function tests with DLCO and 6-minute walk test and lung perfusion scintigraphy before and 7, 30, 60, 180 and 360 days after treatment.

For each patient, 2×107 cells will be labeled with 99mTc. Briefly, 500 μl of sterile SnCl2 solution is added to the cells and the mixture is incubated at room temperature for 10 min. Forty-five mCi of 99mTc is then added and incubation continued for another 10 min. After centrifugation (500×g for 5 min), the supernatant is removed and the cells are washed in saline solution. The pellet was also resuspended in saline solution. Viability of the labeled cells was assessed by the trypan blue exclusion test, and was estimated to be greater than 93% in all cases. Labeling efficiency (%) was calculated by the activity in the pellet divided by the sum of the radioactivity in the pellet plus supernatant and was estimated to be greater than 90% in all cases. Whole body and planar scans will be performed 2 and 24h after instillation. Perfusion scintigraphy will be performed before and 30, 60, 120 and 180 days after BMDMC therapy. For regional analysis the right and left lungs will be divided into three zones: base, midzone, and apex.
Mepivacaine stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia.

Mepivacaine is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the urine. Mepivacaine because of its amide structure, is not detoxified by the circulating plasma esterases. The liver is the principal site of metabolism, with over 50 percent of the administered dose being excreted into the bile as metabolites. Most of the metabolized Mepivacaine is probably resorbed in the intestine and then excreted into the urine since only a small percentage is found in the feces. The principal route of excretion is via the kidney. Most of the anesthetic and its metabolites are eliminated within 30 hours. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of Mepivacaine have been identified from adult humans: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2’, 6’ - pipecoloxylidide).

The onset of action is rapid (30 to 120 seconds in the upper jaw; 1 to 4 minutes in the lower jaw) and Mepivacaine HCl 3% (30 mg/mL) will ordinarily provide operating anesthesia of 20 minutes in the upper jaw and 40 minutes in the lower jaw.

Mepivacaine HCl 2% (20 mg/mL) with Levonordefrin 1:20,000 provides anesthesia of longer duration for more prolonged procedures, 1 hour to 2.5 hours in the upper jaw and 2.5 hours to 5.5 hours in the lower jaw.

Mepivacaine does not ordinarily produce irritation or tissue damage.

Levonordefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of Epinephrine but it is more stable than Epinephrine.

In equal concentrations, Levonordefrin is less potent than Epinephrine in raising blood pressure, and as a vasoconstrictor.
This study will include 20 healthy subjects with intact skin on their lower legs that meet inclusion criteria below. Participants will serve as their own control, by heating one leg and not the other. The radiofrequency device consists of a 4 by 6 inch heating pad connected to a temperature controller. The pad will be applied to the back of the leg and will covered using a compression stocking. The other leg will receive a pad and compression stocking, but radiofrequency will not be applied (no heating).

At the first visit, subjects will be asked to fill out a healthcare questionnaire. With each weekly treatment, subjects will be evaluated to assess how their legs feel on a scale of 1-10, with 1 being no discomfort and 10 being intense pain. Their legs will be photographed before and after radiofrequency MH to examine any visible changes to the tissue. Study team will then use a PeriScan PIM 3 System Laser Doppler scanning for blood perfusion before the Thermofield treatment. The radiofrequency will be set to achieve 40°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 40°C, and the treatment time with consistent temperature application will be 30 minutes. Study team will then use a PeriScan PIM 3 System Laser Doppler scanning for blood perfusion after the Thermofield treatment ends. Study team will take thermal imaging photographs of the treatment area following each treatment.

Subjects will receive weekly treatments for 4 weeks, and will be re-evaluated 4 weeks after the last treatment to assess any tissue changes that continue after the treatments have concluded. Subjects will be excluded from the study if they develop any kind of intolerance to the MH treatment, like increased pain or unexpected skin changes. If they receive a significant injury or wound that is not due to the study, such that the skin of the lower leg is no longer intact, they will be excluded from the study.
The present invention relates to a hangover curing agent and, more specifically, to a hangover curing agent which includes oxygen water containing oxygen bubbles of greater than or equal to a predetermined concentration. The oxygen bubbles are generated by injecting oxygen in a cavitation vacuum which is generated by injecting ultrasonic waves of a predetermined range into water. According to the hangover curing agent and a manufacturing method thereof, the hangover curing agent includes oxygen water containing oxygen bubbles of greater than or equal to a predetermined concentration, wherein the oxygen bubbles are generated by injecting the oxygen in the cavitation vacuum which is generated by injecting the ultrasonic waves of the predetermined range into the water. Thus, the high concentrated oxygen bubbles can be equally and efficiently maintained by being dissolved in water, and are excellent in curing a hangover. That is, the water including the oxygen bubbles is easy to be drunk while suffering from the hangover as not having a taste or a scent, and is economical. In addition, the oxygen bubbles enable to dissolve gas in water and maintain the dissolved gas in water by using the ultrasonic waves.
Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define "high risk for preterm birth" as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding.
Participants diagnosed with idiopathic macular hole(IMH) requiring PPV were enrolled in the IMH group, and this group was a control group because the vitreous of IMH may be closest to normal and normal people do not undergo PPV. 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
ABSTRACT Embodiments of the present invention provide for assessing the state of an 'Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 'Rb, 'Sr, or "Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 825r/82Rb generator of the system may be halted so as to prevent a user from perfomiing an end-run around these quality control mechanisms of the 'Rb elution system. Date Recue/Date Received 2020-07-06
Research in the adult population has evaluated incidence and severity of post-neurosurgical pain, and effectiveness of different post-neurosurgical analgesic regimens. Several small studies report the prevalence of some period of moderate to severe pain in the first 24 postoperative hours to be from 41 to 84 % of patients. In a prospective single academic medical institution study, adult patients treated with only acetaminophen and modest amounts of opioids on an as needed basis reported moderate to severe pain for the first 2 days after surgery. These findings have supported a growing consensus that perioperative pain associated with intracranial surgery may be more significant than initially appreciated. Factors that have been associated with increased pain after intracranial surgery include sex, younger age, surgical site, and surgical approach to the site. Pain may also be a significant factor in the quality of recovery from intracranial surgery. In contrast there are few studies describing the incidence or management of pain after neurosurgery in children.
Through this cohort study, previous clinical data can be systematically reviewed and supplemented by follow-up visits. Prospective enrollment and follow-up of subsequent patients can also be carried out to build a retrospective-prospective two-way cohort study. The preoperative situation (general statistical information, educational level, preoperative clinical function score, etc.), intraoperative situation (operative time, intraoperative blood loss, intraoperative complications, etc.), perioperative situation (total postoperative blood loss, blood transfusion rate, postoperative complications, etc.) and clinical follow-up situation were comprehensively and objectively compared with surgical robot, computer navigation, personalized osteotomy guide and other digital technologies and traditional TKA We summarized and reported the results and conclusions of the center (postoperative force line, implant location, pain, mobility, clinical function score, patient satisfaction and postoperative complications, etc.) and health economics (average length of stay, hospitalization cost, etc.) to provide reference for clinical diagnosis and follow-up research.
A 52-year-old woman presented to our hospital with chief complaints of upper abdominal bloating and lower leg edema. Computed tomography (CT) revealed liver metastasis from a gallbladder tumor. This tumor was diagnosed as neuroendocrine carcinoma (NEC) on performing a biopsy. Physical examination revealed a moon face. Blood tests revealed hypokalemia and high levels of adrenocorticotropic hormone (ACTH) and cortisol. Dexamethasone suppression test revealed that cortisol secretion was not suppressed, and the patient was diagnosed with gallbladder NEC and ectopic ACTH syndrome (EAS). Metyrapone was administered to suppress cortisol production; however, she developed septic shock due to cellulitis in the lower leg and died on the 16th day of admission. A pathological autopsy was performed, which revealed disseminated intravascular coagulation and acute respiratory distress syndrome as the cause of death. Only a few cases of EAS due to NEC originating from the gallbladder have been reported. The patient reported here succumbed shortly after diagnosis, thereby highlighting the challenges in treating gallbladder NEC complicated by EAS.
The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
Hydroxychloroquine (HCQ) is an anti-malarial drug that is used to treat a variety of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, juvenile idiopathic arthritis and Sjogren's syndrome. Hydroxychloroquine is a less toxic metabolite of chloroquine. There is an ongoing increase in the number of patients who are using HCQ for prolonged duration because of the expanding indications and the relatively safe systemic profile.

Hydroxychloroquine can cause variable ocular adverse effects including corneal deposits, posterior sub-capsular cataract, ciliary body dysfunction and toxic retinopathy. Toxic retinopathy caused by HCQ has been recognized for many years. Patients with toxic retinopathy usually complain of blurry vision. The classical clinical picture of HCQ toxic retinopathy is a bilateral bull's-eye maculopathy, which is caused by a ring of parafoveal RPE depigmentation that spares the fovea. The exact mechanism responsible for the development of this pattern is not fully understood, however, it is believed that the primary damage is in the photoreceptors and outer nuclear layer leading to secondary disruption of the RPE.
This is a randomized phase II trial with an internal control. The randomization will be a 1:2:2 randomization (control: experimental arm 1: experimental arm 2). Potentially eligible patients will be screened centrally for the HER-2 status. After confirmation of HER-2 positive disease, eligible patients will be centrally randomized through the EORTC randomization system. A minimization technique will be used for random treatment allocation between the three treatment arms. Stratification will be done by histological subtype (intestinal/non-intestinal); Korea versus Europe; stage II versus III; node positive versus node negative.
PROBLEM TO BE SOLVED: To obtain a new nucleic acid for e.g. production of an animal model of a nerve-denatured disease, comprising a recombinant nucleic acid encoding a protein or peptide involved in a nerve-denatured disease and capable of regenerating a bad regulation of a cell involved in coagulation of protein. SOLUTION: This new recombinant nucleic acid encoding a protein or peptide involved in a nerve-denatured disease is to have been altered as to enable the protein or peptide to concentrate in a predetermined cellar fraction and useful for e.g. producing the cells and animal models of nerve-denatured diseases capable of regenerating a bad regulation of cells involved in concentration of protein. The recombinant nucleic acid is obtained by adding a nucleic acid sequence corresponding to a secretion sequence, which permits a secretion in an endoplasmic reticulum and encodes a series of hydrophobic amino acids, to the upstream of a sequence encoding a β-peptide so as to concentrate a β-amyloid peptide involved in a nerve-denatured disease e.g. Alzheimer's disease in a predetermined cellar fraction, and by adding a KDEL amino acid linkage to the downstream.
Manual debridement is a technique that has existed since 1952 and whose objective is to remove the irregular epithelium by scraping with an instrument, thus allowing the formation of a new superficial layer. Some surgeons use 20% ethanol which they apply to the cornea to debride it before using a blade or sponge to complete the procedure. In this technique, the basement membrane is preserved. This method is still used being simple and cost effective. Its effectiveness in the treatment of recurrent corneal erosions is demonstrated by a success rate estimated at 85%. Thus, it is one of the methods of treating epithelial basement membrane dystrophy. However, the recurrence rate associated with manual debridement is up to 24%, and the average duration before a first recurrence is estimated at 6 months. The formation of corneal opacities was recorded between 7 and 41 days following the intervention.
<P>PROBLEM TO BE SOLVED: To obtain water for cosmetics, usable as a solvent or a dispersion medium for the cosmetics, and prepare a cosmetic free from the problems of conventional cosmetics and giving good effect to skin.  <P>SOLUTION: The water for the cosmetics usable as the solvent or the dispersion medium of the cosmetics dissolves or disperses cosmetic materials. The water contains magnesium, potassium, selenium, cobalt and molybdenum as active components practically in an ionized state, i.e. in dissolved state. The use of the cosmetic containing the water as the solvent or the dispersion medium is effective for permeating the minerals contained in the cosmetic water as active components from the surface to the inner part of the skin to activate the cells, assisting the action of vitamins and enzymes to renovate the cells to healthy state and forming a glossy and moist skin in combination with the effect of the cosmetic materials.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To concentrate a crude drug extract, by dehydrating the crude drug extract by the permeative evaporation method using a hydrophilic semipermeable membrane. CONSTITUTION:A crude drug extract is dehydrated by the permeative evaporation method using a hydrophilic semipermeable membrane [the separation coefficient alphaA/B (A=water, B=ethanol) of 50wt% ethanol water mixture is >=5, more preferably >=10; the rate of permeation of water in the above water- ethanol mixture through said membrane is >=100g/hr.m<2>)]. The remaining trace of water is removed e.g. by freeze-drying, and the product is pulverized to obtain the crude drug rich in the drug component in an extremely high efficiency. The permeative evaporation method is a process for separating a liquid mixture by supplying the liquid mixture to the liquid feed side of the membrane, and evaporating the permeable substance permeated through the membrane at the low pressure side of the membrane maintained at a pressure of <=100mm.Hg. The concentration can be carried out under proper temperature condition according to the properties of the crude drug extract to be treated.
The invention provides a formula of a traditional Chinese medicine for treating coccidiosis of livestock and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine is prepared from radix sophorae flavescentis, rhubarb, cortex phellodendri, cortex magnoliae officinalis, amomum tsao-ko, brucea javanica, portulaca oleracea and palm bark. The preparation dosage is in the form of oral liquid. Water is added to the traditional Chinese medicine, the traditional Chinese medicine is decocted, filtered and concentrated and subjected to filling, sealing and sterilization, and then the traditional Chinese medicine oral liquid for treating coccidiosis of livestock is obtained. According to the formula and the preparation method, radix sophorae flavescentis, amomum tsao-ko and brucea javanica have a pest killing effect, and cortex phellodendri, cortex magnoliae officinalis and portulaca oleracea can diminish inflammation and kill bacteria and can relieve a series of symptoms caused by enteritis while treating enteritis; portulaca oleracea and palm bark have effects of clearing heat and stanching bleeding and can relieve the situation of esophagogastric varices of sicken livestock. The preparation dosage is in the form of oral liquid, the acceptable daily intake of sicken livestock can be controlled due to the oral liquid, and the traditional Chinese medicine is convenient to take, high in palatability, easy to absorb and quick in effect.
This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
The invention relates to a device for delivery of active agent formulation for increasing its organic bioavailability through absorption deeply in the lungs. The inspiration flow rate shall be kept at less than 17 liters per minute for the bioavailability to grow. The active agents, insulin in particular, delivered through the lungs help keep the desired glucose levels in the patientÆs blood. The device consists of a restrictor (302) keeping the aerosolized active agent formulation flow rate below 17 liters per minute. The restrictor (302) may keep the inspired flow rate down to a level lower or equal to 10 liters per minute. Besides, the device is adapted to aerosolize the formulation of an active agent in the form of powder, solution, suspension or pulp that can be pulverized, suspendedor dissolved in propellant.
INTRODUCTION: Esophageal inflammatory fibroid polyp (IFP) is a rare benign tumor of the gastrointestinal tract with limited available data on clinicopathologic features and treatment strategies.
EVIDENCE ACQUISITION: A systematic review of the literature in PubMed/Medline and Scopus databases was performed for articles concerning esophageal IFP in adult population.
EVIDENCE SYNTHESIS: A total of 16 studies were identified, involving 16 patients with a Male-Female Ratio of 3:1 and mean age of 50.38 years. Clinical presentation of esophageal IFP included progressive dysphagia in 56.3% of cases, with additional symptoms such as epigastric and retrosternal pain, weight loss, vomiting, and melena. Diagnostic modalities involved endoscopy in all cases, with endoscopic ultrasound (EUS) employed in 50% of cases and tissue biopsy performed during endoscopy in 87.5% of the patients. Therapeutic approach of esophageal IFP consisted of surgical resection in 75% of the patients and endoscopic resection in the remaining 25%, with various surgical procedures employed based on tumor location. Follow-up data, available for 11 patients over a median duration of 15.5 months, indicated two instances of recurrence following endoscopic resection, while the other nine patients remained asymptomatic with no evidence of recurrence.
CONCLUSIONS: Esophageal IFP is a rare benign tumor of the gastrointestinal tract presenting with dysphagia, regurgitation, and heartburn. Resection, either endoscopic or surgical, is the primary treatment approach. Prognosis for esophageal IFP is favorable, with low recurrence rates. Further research is required to investigate potential risk factors and etiology for this lesion, and to explore novel therapeutic approaches that may improve patient outcomes.